ArticleMMWR. Morbidity and mortality weekly report2026
Kaposi Sarcoma-Associated Herpesvirus Infection and Complications Among Solid Organ Transplant Recipients - United States, January 2021-September 2025.
Article in MMWR. Morbidity and mortality weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kaposi sarcoma-associated herpesvirus (KSHV) infection is the cause of Kaposi sarcoma (KS), certain lymphoproliferative disorders, and the inflammatory condition Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS). In solid organ transplant recipients, KSHV-related complications can result from reactivation of latent infection, new posttransplant infection, or transmission of virus from the transplanted organ. However, testing of donors and recipients is not routinely performed. During January 2021-September 2025, after transplantation of 185 organs into 153 recipients, 46 deceased donors were identified whose transplanted organs were suspected of having transmitted KSHV, approximately five times the number of such donors (nine) reported during 2016-2020. As of February 2026, a posttransplantation KSHV infection has been identified among 74 (48%) of these 153 transplant recipients. Among the 74 recipients with KSHV infection, 45 (61%) developed KS; 10 (14%) of these recipients with KS also developed a lymphoproliferative disorder (multicentric Castleman disease [eight], posttransplant lymphoproliferative disorder [one], and primary effusion lymphoma [one]) and six (8%) developed KICS; four (5%) recipients developed a lymphoproliferative disorder alone (primary effusion lymphoma [one] and posttransplant lymphoproliferative disorder [three]); and one (1%) developed KICS alone. To date, 25 (16%) of the 153 transplant recipients have died. Most donors and recipients were HIV-negative, and nonmedical drug use was common among donors. Clinicians should maintain a high index of suspicion for KSHV in transplant recipients, particularly when donors have risk factors including nonmedical drug use, or when another recipient from the same donor is found to be infected. Development and implementation of effective testing strategies and timely reporting could guide clinical management, reduce risk for KSHV-related complications, and improve transplant safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.